BioRegenx, Inc. (BRGX)

Market Cap	7.75M -59.5%
Revenue (ttm)	1.85M -20.8%
Net Income	-1.54M
EPS	-0.00
Shares Out	969.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	65,226
Open	0.0080
Previous Close	0.0090
Day's Range	0.0080 - 0.0080
52-Week Range	0.0075 - 0.0300
Beta	-3.02
RSI	41.20
Earnings Date	May 21, 2026

About BioRegenx

BioRegenx, Inc. develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally. The company offers Endocalyx Pro, a dietary supplement targeting microvascular capillary health and a range of other supplements under the MyBodyRx brand name; GlycoCheck software; and other health and wellness devices, such as pulsed electro-magnetic field devices, as well as StimaWELL and ReLounge, an electronic muscle stimulation therapy device; and markets hydrogen water products. It also ...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: William Resides
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: BRGX

Financial Performance

In 2025, BioRegenx's revenue was $1.85 million, a decrease of -20.75% compared to the previous year's $2.34 million. Losses were -$1.54 million, -93.30% less than in 2024.